BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29085338)

  • 21. Comparative Cyto-Histological Genetic Profile in a Series of Differentiated Thyroid Carcinomas.
    Matos ML; Pinto M; Alves M; Canberk S; Gonçalves A; Bugalho MJ; Papoila AL; Soares P
    Diagnostics (Basel); 2024 Jan; 14(3):. PubMed ID: 38337794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of molecular testing in fine-needle aspiration biopsy samples: an experience in a Chinese population.
    Liu S; Gao A; Zhang B; Zhang Z; Zhao Y; Chen P; Ji M; Hou P; Shi B
    Exp Mol Pathol; 2014 Oct; 97(2):292-7. PubMed ID: 25111330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ultrasonographic features associated with malignancy in cytologically indeterminate thyroid nodules.
    Batawil N; Alkordy T
    Eur J Surg Oncol; 2014 Feb; 40(2):182-6. PubMed ID: 24373298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular Diagnosis Using Residual Liquid-Based Cytology Materials for Patients with Nondiagnostic or Indeterminate Thyroid Nodules.
    Kwon H; Kim WG; Eszlinger M; Paschke R; Song DE; Kim M; Park S; Jeon MJ; Kim TY; Shong YK; Kim WB
    Endocrinol Metab (Seoul); 2016 Dec; 31(4):586-591. PubMed ID: 27834083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates.
    Marchetti I; Lessi F; Mazzanti CM; Bertacca G; Elisei R; Coscio GD; Pinchera A; Bevilacqua G
    Thyroid; 2009 Aug; 19(8):837-42. PubMed ID: 19534623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules.
    Nikiforov YE; Steward DL; Robinson-Smith TM; Haugen BR; Klopper JP; Zhu Z; Fagin JA; Falciglia M; Weber K; Nikiforova MN
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2092-8. PubMed ID: 19318445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contribution of the BRAF mutation analysis in calcified thyroid nodules.
    Yoo EY; Shin JH; Ko EY; Han BK
    AJR Am J Roentgenol; 2012 Apr; 198(4):891-5. PubMed ID: 22451557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thyroid nodules with KRAS mutations are different from nodules with NRAS and HRAS mutations with regard to cytopathologic and histopathologic outcome characteristics.
    Radkay LA; Chiosea SI; Seethala RR; Hodak SP; LeBeau SO; Yip L; McCoy KL; Carty SE; Schoedel KE; Nikiforova MN; Nikiforov YE; Ohori NP
    Cancer Cytopathol; 2014 Dec; 122(12):873-82. PubMed ID: 25132659
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF V600E mutation analysis of thyroid nodules needle aspirates in relation to their ultrasongraphic classification: a potential guide for selection of samples for molecular analysis.
    Nam SY; Han BK; Ko EY; Kang SS; Hahn SY; Hwang JY; Nam MY; Kim JW; Chung JH; Oh YL; Shin JH
    Thyroid; 2010 Mar; 20(3):273-9. PubMed ID: 20187782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thyroid cytology and the risk of malignancy in thyroid nodules: importance of nuclear atypia in indeterminate specimens.
    Kelman AS; Rathan A; Leibowitz J; Burstein DE; Haber RS
    Thyroid; 2001 Mar; 11(3):271-7. PubMed ID: 11327619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histopathology of telomerase reverse transcriptase promoter (
    Pinto JO; Livhits MJ; Yeh MW; Kaykov A; Klopper JP; Kloos RT; Alshalalfa M; Hao Y; Huang J; Endo M
    J Clin Transl Endocrinol; 2024 Mar; 35():100329. PubMed ID: 38116167
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence and prediction of malignancy in cytologically indeterminate thyroid nodules.
    Sahin M; Gursoy A; Tutuncu NB; Guvener DN
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):514-8. PubMed ID: 16984245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer.
    Monti E; Bovero M; Mortara L; Pera G; Zupo S; Gugiatti E; Dono M; Massa B; Ansaldo GL; Massimo G
    Int J Endocrinol; 2015; 2015():138734. PubMed ID: 26693224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology.
    Cantara S; Capezzone M; Marchisotta S; Capuano S; Busonero G; Toti P; Di Santo A; Caruso G; Carli AF; Brilli L; Montanaro A; Pacini F
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1365-9. PubMed ID: 20130073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases.
    Insilla AC; Proietti A; Borrelli N; Macerola E; Niccoli C; Vitti P; Miccoli P; Basolo F
    Oncol Lett; 2018 Mar; 15(3):2763-2770. PubMed ID: 29435002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology.
    Nikiforov YE; Carty SE; Chiosea SI; Coyne C; Duvvuri U; Ferris RL; Gooding WE; LeBeau SO; Ohori NP; Seethala RR; Tublin ME; Yip L; Nikiforova MN
    Thyroid; 2015 Nov; 25(11):1217-23. PubMed ID: 26356635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytomorphologic features in thyroid nodules read as "suspicious for malignancy" on cytology may predict thyroid cancers with the BRAF mutation.
    Kwon HJ; Kim EK; Kwak JY
    Pathol Res Pract; 2015 Sep; 211(9):671-6. PubMed ID: 26187369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of malignancy rate in thyroid nodules with cytology of indeterminate follicular or indeterminate Hürthle cell neoplasm.
    Sorrenti S; Trimboli P; Catania A; Ulisse S; De Antoni E; D'Armiento M
    Thyroid; 2009 Apr; 19(4):355-60. PubMed ID: 19355826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings.
    Sapio MR; Posca D; Raggioli A; Guerra A; Marotta V; Deandrea M; Motta M; Limone PP; Troncone G; Caleo A; Rossi G; Fenzi G; Vitale M
    Clin Endocrinol (Oxf); 2007 May; 66(5):678-83. PubMed ID: 17381488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical role of BRAF V600E mutation testing in thyroid nodules].
    Wan H; Zhang B; Wang Y; Xiao T; Guo H; Liu W; Yan D; Xu Z; Tang P
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Jun; 49(6):468-72. PubMed ID: 25241863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.